SavedAdd your journal

Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2014 / Cilt: 24 - Sayı: 4

Evre IIIB-IV Küçük Hücre Dışı Akciğer Kanseri Hastalarında Eşlik Eden Komobiditelerin Sağkalım Üzerine Etkisi

Impact of Accompanying Comorbidities on Survival in Patients with Stage IIIB- IV Non-Small-Cell Lung Cancer

Mustafa DEMİRPENÇE
Tülay AKMAN
İlhan ÖZTOP
Ilkay T. UNEK
TUĞBA YAVUZŞEN
Ahmet U. YILMAZ
Pages
223–232
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, the frequency of comorbidity factors increased in stage IIIB and IV NSCLC patients as age increased.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of the study was to investigate the impact of accompanying comorbidities on survival in non-small-cell lung carcinoma (NSCLC) patients.
📊
Key Findings & Data:A total of 221 patients with stage IIIB- IV NSLC between May 1998 and April 2009 were included.
💡
Conclusion & Impact:In conclusion, the frequency of comorbidity factors increased in stage IIIB and IV NSCLC patients as age increased.
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

The aim of the study was to investigate the impact of accompanying comorbidities on survival in non-small-cell lung carcinoma (NSCLC) patients. A total of 221 patients with stage IIIB- IV NSLC between May 1998 and April 2009 were included. Survival data was analyzed according to age (those younger than 65 and those 65 and older) and Charlson Comorbidity Index (CCI) scores. Eighty-six (39%) patients were aged 65 and older, and the remaining 135 (61%) were younger than 65. In the 65 and over group the median survival of patients was 44 months for CCI Group 0, 16 months for CCI Group 1, 10 months for CCI Group 2, and 10 months for CCI Group 3. For the younger group, the median survival time was 19 months for CCI Group 0, 18 months for CCI Group 1, 11 months for CCI Group 2, and 11 months for CCI Group 3. There were no statistically significant differences in the comorbidity factors regarding survival in the two groups of patients. In conclusion, the frequency of comorbidity factors increased in stage IIIB and IV NSCLC patients as age increased. Although survival in patients with higher CCI scores was shorter, the CCI was not associated with survival for patients having local advanced and metastatic disease; no significant difference was found statistically for these patients. Therefore, these patients need to be managed more thoroughly

Özet

Bu çalışmanın amacı Küçük Hücreli Dışı Akciğer Kanserli (KHDAK) hastalarda komorbid faktörlerin sağkalım üzerine olan etkisinin araştırılmasıdır. Mayıs 1998 ile Nisan 2009 tarihleri arasında, histopatolojik olarak KHDAK tanısı almış, evre IIIB ve IV olan toplam 221 hasta çalışmaya alınmıştır. Sağkalım verileri yaşa (65 yaş ve üstü ve 65 yaş altı) ve Charlson Komorbidite İndeksine (CKİ) göre değerlendirildi. 86 hasta (%39) 65 ve üzeri yaşta, geri kalan 135 (%61) hasta 65 yaşından az idi. 65 yaş ve üzeri grupta CKİ’ye göre değerlendirildiğinde median sağkalım Grup 0 için 44 ay, Grup 1 için 16 ay, Grup 2 için 10 ay, Grup 3 için 10 ay olarak saptandı. Genş yaştaki grupta, median sağkalım Grup 0 için 19 ay, Grup 1 için 18 ay, Grup 2 için 11 ay, Grup 3 için 11 ay olarak saptandı. İki grup arasında sağkalımı etkileyen komorbit faktörler değerlendirildiğinde istatiksel anlamlı farklılık saptanmadı. Sonuç olarak, Evre IIIB ve IV KHDAK hastalarda yaş arttıkça komorbid faktörlerin sıklığının arttığı ancak yaş bakımından sağkalımda anlamlı bir fark olmadığı saptanmıştır. Charlson Komorbidite İndeks skorları yüksek olanlarda sağkalımın kısa olması bu hastalara daha titizlikle yaklaşılmasını gerektirmektedir.

🔖

Cite This Article

DEMİRPENÇE, M., AKMAN, T., ÖZTOP, İ., UNEK, I. T., YAVUZŞEN, T., YILMAZ, A. U. (2014). Evre IIIB-IV Küçük Hücre Dışı Akciğer Kanseri Hastalarında Eşlik Eden Komobiditelerin Sağkalım Üzerine Etkisi. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 24 - Sayı: 4, 223–232. https://ajindex.com/articles/322876

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer: search and destroy. Eur J Cancer 42: 17-23, 2006.
  2. Spigel DR, Greco FA. Chemotherapy in metastatic and locally advanced non-small cell lung cancer. Semin Surg Oncol 21: 98-110, 2003.
  3. Fried LP, Bandeen-Roche K, Kasper JD, Guralnik JM. Association of comorbidity with disability in older women: the Women’s Health and Aging Study. J Clin Epidemiol 52: 27- 37, 1999.
  4. Janssen-Heijnen ML, Smulders S, Lemmens VE, et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 59: 602-607, 2004.
  5. Janssen-Heijnen ML, Schipper RM, Razenberg PP, et al. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 21,105-13, 1998.
  6. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Impact of comorbidity on lung cancer survival. Int J Cancer 103: 792-802, 2003.
  7. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373- 383, 1987.
  8. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16: 1582-1587, 1998.
  9. Greenfield S, Blanco DM, Elashoff RM, Ganz PA. Patterns of care related to age of breast cancer patients. JAMA 257: 2766-2770, 1987.
  10. Imamura K, McKinnon M, Middleton R, Black N. Reliability of a comorbidity measure: the Index of Co-Existent Disease (ICED). J Clin Epidemiol 50: 1011-16, 1997.
  11. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluatin the outcome of diabetes mellitus. J Chronic Dis 27: 387-404, 1974.
  12. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 16: 622-626, 1968.
  13. Abali H, Ata A, Ozdogan M, et al. Frequency of comorbid illnesses in cancer patients in Turkey. J BUON 16: 557-560, 2011.
  14. Moro-Sibilot D, Aubert A, Diab S, et al. Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer. Eur Respir J 26: 480-486, 2005.
  15. Birim O, Maat AP, Kappetein AP, et al. Validation of the Charlson comorbidity index in patients with operated primary nonsmall cell lung cancer. Eur J Cardiothorac Surg 23: 30-34, 2003.
  16. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest 117: 1239-46, 2000.
  17. Asmis TR, Ding K, Seymour L, et al. Age and comorbidity